DI
LGND icon

Disciplined Investments’s Ligand Pharmaceuticals LGND Stock Holding History

Disciplined Investments’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-2
Closed -$144 – 900
2023
Q2 		$144 Hold
2
– – ﹤0.01% 1555
2023
Q1 		$147 Hold
2
– – ﹤0.01% 1535
2022
Q4 		$134 Sell
2
-1
-33% -$65 ﹤0.01% 1501
2022
Q3 		$0 Hold
3
– – ﹤0.01% 1429
2022
Q2 		$0 Hold
3
– – ﹤0.01% 1463
2022
Q1 		$0 Buy
+3
New +$218 ﹤0.01% 1493

Other funds holding LGND

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return
SDJVC
St. Denis J. Villere & Co New Orleans, Louisiana $907M AUM 10.61% 1-Year Est. Return
CC
Chicago Capital Chicago, Illinois $3.71B AUM 19.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Disciplined Investments's LGND Position: Q3 2023 in Review

Disciplined Investments sold out of Ligand Pharmaceuticals (LGND) in Q3 2023, closing a stake of 2 shares — an estimated $144 sold.

Disciplined Investments first reported a position in LGND in Q1 2022 and held it in 6 quarters. The position peaked at $147 in Q1 2023. 196 funds tracked by Wall St. Rank hold LGND as of Q3 2023.

  • Disciplined Investments reported no remaining Ligand Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
  • Disciplined Investments sold 2 Ligand Pharmaceuticals shares in Q3 2023, an estimated $144.
  • Disciplined Investments first reported a position in Ligand Pharmaceuticals in Q1 2022 and held it in 6 quarters.
  • Disciplined Investments's Ligand Pharmaceuticals position peaked at $147 in Q1 2023.
  • 196 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q3 2023.

Based on Disciplined Investments's 13F filing for Q3 2023, filed 14 Nov 2023.